Startups & Venture Capital

Isomorphic Labs Raises $5 Billion to Advance AI-Designed Drugs

Demis Hassabis’ Isomorphic Labs raises $5 billion in a Series C co-led by Greenoaks and Sequoia, bringing its announced 2026 funding to $7.1 billion.

By Benjamin Harper Edited by Michael Foster Published:
Isomorphic Labs Raises $5 Billion to Advance AI-Designed Drugs
Isomorphic Labs has raised $5 billion to advance AI-designed medicines toward clinical trials. Founder Demis Hassabis is pictured at the 2024 Nobel Lectures. Photo: Jay Dixit / Wikipedia 

Key Notes

  • Isomorphic Labs raised $5 billion in an oversubscribed Series C co-led by Greenoaks and Sequoia Capital, with further backing from Alphabet.
  • The financing follows a $2.1 billion Series B in May, taking announced funding this year to $7.1 billion.
  • Proceeds will support its drug design engine and clinical-development infrastructure as its first therapeutic candidates move toward human trials.

Isomorphic Labs has raised $5 billion to expand its AI drug-discovery business and move its first therapeutic candidates toward clinical trials, giving founder Demis Hassabis fresh backing for his effort to turn advances in artificial intelligence into medicines.

The Series C was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz also participated, while Alphabet (Nasdaq: GOOGL) made a further significant investment. Isomorphic described the round as oversubscribed but did not disclose a valuation.

Funding Reaches $7.1 Billion This Year

The financing follows a $2.1 billion Series B in May. Together, the two announced rounds total $7.1 billion in 2026, with the latest raise more than twice the size of the May financing.

For Sequoia, the investment fits a strategy that puts biology alongside AI among its preferred areas. The venture firm recently disclosed about $10 billion in new funds as it reorganized its investment teams.

Drug Candidates Approach the Clinic

Isomorphic plans to use the money to improve its proprietary drug design engine, IsoDDE, and expand the infrastructure needed to take potential medicines into clinical development.

The system brings together AI simulation models that help researchers explore possible molecules and refine their properties. Isomorphic says its internal oncology and immunology programs, along with work for partners, have produced encouraging preclinical results.

That places the next phase of the business closer to patients. The company is building the research, translational and clinical capabilities needed to move beyond computational predictions and laboratory work into human testing, according to its financing announcement.

Hassabis Puts Biology at the Center

Founded in 2021 as a DeepMind spinout, Isomorphic remains led by Hassabis. He is also Alphabet’s chief scientist and Google DeepMind’s chair, having stepped back from the latter company’s CEO role earlier this year.

In his announcement on X, Hassabis emphasized reducing the time and cost of finding new medicines. The company is now funding the transition from designing potential drugs to building the teams and facilities needed to develop and test them.

Disclaimer: MarketSpeaker content is provided for informational and educational purposes only and does not constitute financial or investment advice. Investing involves risk, including the possible loss of principal. Verify information independently and consult a qualified professional before making financial decisions.

Big Tech & Innovation, News, Startups & Venture Capital